IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v40y2017i3d10.1007_s40264-016-0483-0.html
   My bibliography  Save this article

Benefits and Risks of Long-Term Asthma Management in Children: Where Are We Heading?

Author

Listed:
  • Hengameh H. Raissy

    (University of New Mexico, School of Medicine)

  • H. William Kelly

    (University of New Mexico, School of Medicine)

Abstract

International guidelines provide recommendations for a stepwise approach to the management of asthma in children 0–4 years old, 5–11 years old, and adolescents who are treated as adults. Therapy is aimed at two domains of control: current impairment and future risk. The long-term controller medications, inhaled corticosteroids (ICSs), ICSs in combination with long-acting β2 agonists, leukotriene receptor antagonists, and immunomodulators, exhibit different efficacies for these domains. The risk:benefit ratios of the available medications need to be carefully assessed. This review briefly presents the benefits and the potential risks of available asthma medications in children to assist the practitioner in the optimal use of asthma medications. Specifically, the systemic activity of the ICSs and how to minimize their effects on growth and adrenal activity are reviewed as well as other potential adverse effects. Dosing strategies such as intermittent therapy are also assessed.

Suggested Citation

  • Hengameh H. Raissy & H. William Kelly, 2017. "Benefits and Risks of Long-Term Asthma Management in Children: Where Are We Heading?," Drug Safety, Springer, vol. 40(3), pages 201-210, March.
    • Handle: RePEc:spr:drugsa:v:40:y:2017:i:3:d:10.1007_s40264-016-0483-0
    DOI: 10.1007/s40264-016-0483-0
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-016-0483-0
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40264-016-0483-0?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:40:y:2017:i:3:d:10.1007_s40264-016-0483-0. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.